Literature DB >> 26093188

Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.

Kelly Cleland1, Nicole Smith2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26093188     DOI: 10.1016/j.contraception.2015.06.016

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


× No keyword cloud information.
  5 in total

1.  Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss.

Authors:  Courtney A Schreiber; Mitchell D Creinin; Jessica Atrio; Sarita Sonalkar; Sarah J Ratcliffe; Kurt T Barnhart
Journal:  N Engl J Med       Date:  2018-06-07       Impact factor: 91.245

2.  The burden of the Risk Evaluation and Mitigation Strategy (REMS) on providers and patients experiencing early pregnancy loss: A commentary.

Authors:  Anne N Flynn; Jade M Shorter; Andrea H Roe; Sarita Sonalkar; Courtney A Schreiber
Journal:  Contraception       Date:  2021-04-22       Impact factor: 3.051

3.  In Favor of Discussion on the Amendment of the "Abortion Prohibition Law" in Korea.

Authors:  Mina Lee
Journal:  J Korean Med Sci       Date:  2019-05-20       Impact factor: 2.153

4.  Exploring the impact of mifepristone's risk evaluation and mitigation strategy (REMS) on the integration of medication abortion into US family medicine primary care clinics✰,✰✰.

Authors:  Na'amah Razon; Sarah Wulf; Citlali Perez; Sarah McNeil; Lisa Maldonado; Alison Byrne Fields; Diana Carvajal; Rachel Logan; Christine Dehlendorf
Journal:  Contraception       Date:  2022-02-04       Impact factor: 3.051

Review 5.  The impact of COVID-19 on abortion access: Insights from the European Union and the United Kingdom.

Authors:  Neva Bojovic; Jovana Stanisljevic; Guido Giunti
Journal:  Health Policy       Date:  2021-05-17       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.